Literature DB >> 34224019

In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201.

Vincenzo Abbate1, Samantha Y A Terry2, Katarzyna M Osytek3, Philip J Blower3, Ines M Costa3, Gareth E Smith4.   

Abstract

BACKGROUND: Auger electron-emitting radionuclides have potential in targeted treatment of small tumors. Thallium-201 (201Tl), a gamma-emitting radionuclide used in myocardial perfusion scintigraphy, decays by electron capture, releasing around 37 Auger and Coster-Kronig electrons per decay. However, its therapeutic and toxic effects in cancer cells remain largely unexplored. Here, we assess 201Tl in vitro kinetics, radiotoxicity and potential for targeted molecular radionuclide therapy, and aim to test the hypothesis that 201Tl is radiotoxic only when internalized.
METHODS: Breast cancer MDA-MB-231 and prostate cancer DU145 cells were incubated with 200-8000 kBq/mL [201Tl]TlCl. Potassium concentration varied between 0 and 25 mM to modulate cellular uptake of 201Tl. Cell uptake and efflux rates of 201Tl were measured by gamma counting. Clonogenic assays were used to assess cell survival after 90 min incubation with 201Tl. Nuclear DNA damage was measured with γH2AX fluorescence imaging. Controls included untreated cells and cells treated with decayed [201Tl]TlCl.
RESULTS: 201Tl uptake in both cell lines reached equilibrium within 90 min and washed out exponentially (t1/2 15 min) after the radioactive medium was exchanged for fresh medium. Cellular uptake of 201Tl in DU145 cells ranged between 1.6 (25 mM potassium) and 25.9% (0 mM potassium). Colony formation by both cell lines decreased significantly as 201Tl activity in cells increased, whereas 201Tl excluded from cells by use of high potassium buffer caused no significant toxicity. Non-radioactive TlCl at comparable concentrations caused no toxicity. An estimated average 201Tl intracellular activity of 0.29 Bq/cell (DU145 cells) and 0.18 Bq/cell (MDA-MB-231 cells) during 90 min exposure time caused 90% reduction in clonogenicity. 201Tl at these levels caused on average 3.5-4.6 times more DNA damage per nucleus than control treatments.
CONCLUSIONS: 201Tl reduces clonogenic survival and increases nuclear DNA damage only when internalized. These findings justify further development and evaluation of 201Tl therapeutic radiopharmaceuticals.

Entities:  

Keywords:  201Tl; Auger electrons; Radiobiology; Targeted molecular radionuclide therapy; Thallium-201

Year:  2021        PMID: 34224019     DOI: 10.1186/s13550-021-00802-w

Source DB:  PubMed          Journal:  EJNMMI Res        ISSN: 2191-219X            Impact factor:   3.138


  21 in total

Review 1.  Technetium-99m labeled myocardial perfusion imaging agents.

Authors:  D Jain
Journal:  Semin Nucl Med       Date:  1999-07       Impact factor: 4.446

2.  Thallium-201 for medical use. I.

Authors:  E Lebowitz; M W Greene; R Fairchild; P R Bradley-Moore; H L Atkins; A N Ansari; P Richards; E Belgrave
Journal:  J Nucl Med       Date:  1975-02       Impact factor: 10.057

3.  EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology.

Authors:  B Hesse; K Tägil; A Cuocolo; C Anagnostopoulos; M Bardiés; J Bax; F Bengel; E Busemann Sokole; G Davies; M Dondi; L Edenbrandt; P Franken; A Kjaer; J Knuuti; M Lassmann; M Ljungberg; C Marcassa; P Y Marie; F McKiddie; M O'Connor; E Prvulovich; R Underwood; B van Eck-Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

Review 4.  The clinical significance of unusual sites of thallium-201 uptake.

Authors:  A Z Krasnow; B D Collier; A T Isitman; R S Hellman; D C Peck
Journal:  Semin Nucl Med       Date:  1988-10       Impact factor: 4.446

5.  Difference in 201Tl accumulation on single photon emission computed tomography in benign and malignant thoracic lesions.

Authors:  K Suga; N Kume; N Orihashi; K Nishigauchi; H Uchisako; T Matsumoto; N Yamada; T Nakanishi
Journal:  Nucl Med Commun       Date:  1993-12       Impact factor: 1.690

6.  Thallium-201 scintigraphy is an effective diagnostic modality to distinguish malignant from benign soft-tissue tumors.

Authors:  Naoaki Kawakami; Toshiyuki Kunisada; Shuhei Sato; Yuki Morimoto; Masato Tanaka; Tsuyoshi Sasaki; Shinsuke Sugihara; Hiroyuki Yanai; Susumu Kanazawa; Toshifumi Ozaki
Journal:  Clin Nucl Med       Date:  2011-11       Impact factor: 7.794

7.  Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response.

Authors:  L Ramanna; A Waxman; G Binney; S Waxman; J Mirra; G Rosen
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

8.  Experimental study on tumor affinity of 201T1-chloride.

Authors:  Y Ito; A Muranaka; T Harada; A Matsudo; T Yokobayashi; H Terashima
Journal:  Eur J Nucl Med       Date:  1978-04-01

Review 9.  Targeting the nucleus: an overview of Auger-electron radionuclide therapy.

Authors:  Bart Cornelissen; Katherine A Vallis
Journal:  Curr Drug Discov Technol       Date:  2010-12

Review 10.  Auger electrons for cancer therapy - a review.

Authors:  Anthony Ku; Valerie J Facca; Zhongli Cai; Raymond M Reilly
Journal:  EJNMMI Radiopharm Chem       Date:  2019-10-11
View more
  4 in total

Review 1.  Non-invasive radionuclide imaging of trace metal trafficking in health and disease: "PET metallomics".

Authors:  George Firth; Julia E Blower; Joanna J Bartnicka; Aishwarya Mishra; Aidan M Michaels; Alex Rigby; Afnan Darwesh; Fahad Al-Salemee; Philip J Blower
Journal:  RSC Chem Biol       Date:  2022-04-11

2.  Relationship of In Vitro Toxicity of Technetium-99m to Subcellular Localisation and Absorbed Dose.

Authors:  Ines M Costa; Noor Siksek; Alessia Volpe; Francis Man; Katarzyna M Osytek; Elise Verger; Giuseppe Schettino; Gilbert O Fruhwirth; Samantha Y A Terry
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

3.  Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.

Authors:  Ramya Ambur Sankaranarayanan; Jennifer Peil; Andreas T J Vogg; Carsten Bolm; Steven Terhorst; Arno Classen; Matthias Bauwens; Jochen Maurer; Felix Mottaghy; Agnieszka Morgenroth
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

4.  Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine.

Authors:  Alex Rigby; George Firth; Charlotte Rivas; Truc Pham; Jana Kim; Andreas Phanopoulos; Luke Wharton; Aidan Ingham; Lily Li; Michelle T Ma; Chris Orvig; Philip J Blower; Samantha Y A Terry; Vincenzo Abbate
Journal:  Bioconjug Chem       Date:  2022-07-08       Impact factor: 6.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.